XOMA is a biopharmaceutical company that discovers, develops and manufactures therapeutic antibodies. These antibodies and other agents are developed in order to treat inflammatory, autoimmune, infections and oncological diseases.
The company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA’s proprietary Human Engineering(tm) and Bacterial Cell Expression (BCE) and manufacturing technologies.
Partnering with companies, such as Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited, enables XOMA to develop additional antibodies with multi-indication potential. Partnering not only allows XOMA access to new drug targets, but will add substantially to the generation of more revenue for the company.
XOMA was awarded a $65 Million multiple year contract from the National Institute of Allergy and infectious Diseases (NIAII). This contract will support XOMAâ€™ s ongoing development of drug candidates towards clinical trials in the treatment of botulism poisoning, which could be a potentially deadly muscle paralyzing disease.
Let us hear your thoughts: XOMA Ltd. Message Board